Akshay Shah
Plymouth, MINPI 1831119981
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $238,461 of the $319,446 with a category attached, or 74.6%. 8 manufacturers reported payments, led by Merck at 35.9% of the total. Reporting peaked in 2019 at $146,357 and has fallen 99.3% since, to $1,000 in 2025.
Across 347 payments — averaging $920.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$115K
- Aimmune Therapeutics, Inc.$91K
- Shionogi Inc$56K
- Insmed, Inc.$43K
- La Jolla Pharmaceutical Company$8K
- Cumberland Pharmaceuticals, Inc.$6K
- plus $739 from 2 others
What the payments were for
- Consulting fees$3,7851%
- Speaking & faculty fees$238,46175%
- Travel & lodging$70,56022%
- Food & beverage$6,4292%
- Education$2110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 158 | $114,601 |
| Aimmune Therapeutics, Inc. | 51 | $91,432 |
| Shionogi Inc | 51 | $56,314 |
| Insmed, Inc. | 76 | $42,563 |
| La Jolla Pharmaceutical Company | 4 | $7,796 |
| Cumberland Pharmaceuticals, Inc. | 4 | $6,000 |
| Paratek Pharmaceuticals, Inc. | 2 | $692 |
| Nestle Healthcare Nutrition Inc. | 1 | $47 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.